Welcome to our dedicated page for Tharimmune SEC filings (Ticker: THAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a small-cap biotech filing can feel like decoding a lab notebook—especially when Tharimmune’s disclosures span pruritus trial endpoints, antibody constructs and complex licensing terms. If you have ever asked, "How do I navigate a Tharimmune annual report 10-K simplified?" or hunted for Tharimmune insider trading Form 4 transactions, you know the challenge.
Stock Titan solves it. Our AI instantly breaks down every document—so understanding Tharimmune SEC documents with AI means plain-English summaries, key financial tables and alerts the moment a Tharimmune Form 4 insider transactions real-time filing hits EDGAR. Need the latest Tharimmune quarterly earnings report 10-Q filing? We tag R&D spend, cash runway and pipeline updates, then link them to historical trends for quick Tharimmune earnings report filing analysis. Material deal signed or FDA feedback released? The platform flags it inside the next 8-K, giving you Tharimmune 8-K material events explained before the market digests the news.
Here’s what investors regularly track:
- Phase-progress timelines, dosing cohorts and safety data tucked into 10-Q footnotes
- Licensing economics and dilution risk revealed in S-3 and S-1 shelves
- Tharimmune executive stock transactions Form 4 that signal insider confidence
- Board pay details inside the Tharimmune proxy statement executive compensation
Stop wading through 200-page PDFs. Stock Titan delivers AI-powered summaries, expert context and real-time updates on every Tharimmune filing—so you can focus on whether TH104’s buccal film or those multi-specific antibodies are the next breakthrough.
Tharimmune, Inc. is a clinical-stage biotech focused on immunology and inflammation programs, including TH104 (buccal film) and oral infliximab programs licensed from Avior and Intract. The company received FDA IND approval for TH104 in February 2023 and reported positive FDA feedback in March 2025 on a Pre-IND request for a prophylactic high-potency opioid indication (PrHPO), where the FDA indicated a 505(b)(2) NDA pathway is feasible with additional nonclinical in vitro toxicology but no new clinical trials expected to define the prophylactic dosing window.
Financially, Tharimmune had $2.24 million in cash and
FAQ
What is the current stock price of Tharimmune (THAR)?
What is the market cap of Tharimmune (THAR)?
